Skip to main content

The most frequent adverse events reported as drug-related or unknown relationship to study drug in the 78 patients and 63 normal volunteers who received Antizol® (fomepizole) Injection were headache (14%), nausea (11%), and dizziness, increased drowsiness, and bad taste/metallic taste (6% each). All other adverse events in this population were reported in approximately 3% or fewer of those receiving Antizol (fomepizole) and were as follows:

Body as a Whole: Abdominal pain, fever, multiorgan system failure, pain during Antizol (fomepizole) injection, inflammation at injection site, lumbalgia/backache, hangover

Cardiovascular: Sinus bradycardia/bradycardia, phlebosclerosis, tachycardia, phlebitis, shock, hypotension

Gastrointestinal: Vomiting, diarrhea, dyspepsia, heartburn, decreased appetite, transient transaminitis

Hemic/Lymphatic: Eosinophilia/hypereosinophilia, lymphangitis, disseminated intravascular coagulation, anemia

Nervous: Lightheadedness, seizure, agitation, feeling drunk, facial flush, vertigo, nystagmus, anxiety, "felt strange", decreased environmental awareness

Respiratory: Hiccups, pharyngitis

Skin/Appendages: Application site reaction, rash

Special Senses: Abnormal smell, speech/visual disturbances, transient blurred vision, roar in ear

Urogenital: Anuria